| Literature DB >> 30469520 |
Gabriele Serreli1, Monica Deiana2.
Abstract
Extra virgin olive oil (EVOO) polyphenols beneficial effects have widely been debated throughout the last three decades, with greater attention to hydroxytyrosol and tyrosol, which are by far the most studied. The main concern about the evaluation of EVOO phenols activities in vitro and in vivo is that the absorption and metabolism of these compounds once ingested lead to the production of different metabolites in the human body. EVOO phenols in the ingested forms are less concentrated in human tissues than their glucuronide, sulfate and methyl metabolites; on the other hand, metabolites may undergo deconjugation before entering the cells and thus act as free forms or may be reformed inside the cells so acting as conjugated forms. In most in vitro studies the presence of methyl/sulfate/glucuronide functional groups does not seem to inhibit biological activity. Parent compounds and metabolites have been shown to reach tissue concentrations useful to exert beneficial effects others than antioxidant and scavenging properties, by modulating intracellular signaling and improving cellular response to oxidative stress and pro-inflammatory stimuli. This review aims to give an overview on the reported evidence of the positive effects exerted by the main EVOO polyphenols metabolites in comparison with the parent compounds.Entities:
Keywords: extra virgin olive oil; homovanillic acid; homovanillyl alcohol; hydroxytyrosol; metabolites; polyphenols; tyrosol
Year: 2018 PMID: 30469520 PMCID: PMC6315336 DOI: 10.3390/antiox7120170
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Hydroxytyrosol and tyrosol metabolites.
Figure 2Luteolin, apigenin and ferulic acid metabolites.
Olive oil polyphenols metabolites and their activities in different in vitro and in vivo experimental models.
| Compounds | Concentration Tested | In Vitro/In Vivo Model | Outcome | Reference |
|---|---|---|---|---|
| Mix of metabolites | 10–80 µM | In vitro red blood cells (RBC) | Protection of red blood cells from H2O2-induced oxidative injury | [ |
| 10 mg/kg | ApoE−/− mice | Reduction of VCAM-1, ICAM-1, E-selectin and MCP-1 molecules secretion by inhibiting mRNA expression | [ | |
| 1–5 μM | Human aortic endothelial cells (HAEC) | Reduction of p38δ, JNK1-3, CREB, AKT3, p53 and P70 S6 kinase phosphorylation, and of lymphocytes adhesion | [ | |
| HT glucuronide | 100 μM | Rat aortic rings | Reduced endothelial dysfunction by blocking superoxide production | [ |
| 2.3 µM | DPPH test | Good antioxidant and antiradical capacity | [ | |
| 0.01–10 μM | In vitro Cu-induced oxidation of LDL | Loss of antioxidant activity with respect to HT | [ | |
| 5–10 μM | Renal LLC-PK1 cells culture model | Protection of renal cells against H2O2-induced lipid peroxidation | [ | |
| 10–25 µM | Human hepatocarcinoma HepG2 cells | Inhibition of tunicamycin-induced endoplasmic reticulum (ER) stress | [ | |
| HT sulfate | 91 µM | DPPH test | Poor antioxidant and antiradical capacity | [ |
| 2.5–10 µM | Caco-2 intestinal cells monolayers | Counteraction of the oxidizing action of oxidized cholesterol on intestinal cell membranes | [ | |
| 10 µM | Neuroblastoma (SH-SY5Y) and dopaminergic (LUHMES) neuronal cells | Protective effects against oxidative stress | [ | |
| Tyr glucuronide | 0.01–10 μM | In vitro Cu-induced oxidation of LDL | Loss of antioxidant activity with respect to Tyr | [ |
| 100 µM | Endothelial HUVEC cells monolayers | Prevention of the phosphorylation of NF-κB signaling proteins and of the over-expression of adhesion molecules | [ | |
| 0.1–0.5 mg/kg | Carrageenan-induced hind paw oedema in mice | Amelioration of plantar and ear edemas | [ | |
| Tyr sulfate | 2.5–10 µM | Intestinal Caco-2 cells monolayers | Counteraction of the oxidizing action of oxidized cholesterol on intestinal cell membranes | [ |
| 0.1–0.5 mg/kg | Carrageenan-induced hind paw oedema in mice | Amelioration of plantar and ear edemas | [ | |
| 100 µM | Endothelial HUVEC cells monolayers | Prevention of the phosphorylation of NF-κB signaling proteins and of the over-expression of adhesion molecules | [ | |
| Homovanillic acid | 14.8 µM | DPPH test | Good antioxidant and antiradical capacity | [ |
| Homovanillyl alcohol | 11.4 µM | DPPH test | Good antioxidant and antiradical capacity | [ |
| 5.4–146.5 mM | Human clinical study | Reduction of CVD and total mortality risk | [ | |
| 0.3–1 µM | Renal LLC-PK1 cell culture model | Protection against H2O2-induced renal epithelial injury through interaction both MAP kinase and PI3 kinase pathways | [ | |
| 2–20 µM | Endothelial HUVEC cells monolayers | Inhibition of ICAM-1, VCAM-1 and MCP-1 secretion | [ | |
| 5–25 µM | Intestinal Caco-2 cells monolayers | Protection of cell membranes from oxidative damage induced by TBH | [ | |
| 0.5–10 mM | Human gastric adenocarcinoma (AGS) cells | Inhibition of NF-kB driven transcription and nuclear translocation | [ | |
| 0.5–25 µM | Endothelial HUVEC cells monolayers | Inhibition of cell surface expression of E-selectin, ICAM-1 and VCAM-1 adhesion molecules | [ | |
| 1–7.5 µM | Human monocytic cells U937 | Reduced cell adhesion and ICAM-1 expression | [ | |
| 10–50 µM | Erythrocytes by blood samples obtained from trisomic patients | Decreased oxidative stress-induced ROS generation | [ | |
| 0.25–1 µM | Peripheral mononucleated blood cells (PBMCs) | Inhibition of oxysterols-induced production of proinflammatory cytokines, interleukin-1β, normal T-cell macrophage migration inhibitory factor. Decreased levels of reactive oxygen species (ROS) and phosphorylation of the p38 and JNK MAP kinases | [ | |
| FA glucuronide | 11.42–114.2 µg/kg | Male Swiss mice | Elicitation of vasorelaxation of saphenous and femoral arteries and aortae. Decreased mean arterial pressure | [ |
| IsoFA | 0.5–1 mg/day | Mice infected by intranasal inoculation of influenza virus | Inhibition of the progression of lethal influenza virus pneumonia | [ |
| 1–13 μg/mL | In vitro lipid peroxidation, DPPH and ABTS tests | Good antioxidant activity | [ | |
| 5.0 mg/kg | Streptozotocin-induced diabetic rats | Inhibition of hepatic gluconeogenesis and increase of the glucose utilization in peripheral tissue to lower plasma glucose | [ | |
| 1.25–5 mM | In vitro Glycation of Bovine Serum Albumin (BSA) | Antiglycation properties against fructose and glucose-mediated glycation and oxidation of bovine serum albumin | [ | |
| HydroFA | 0.01–100 μg/mL | In vitro platelet culture | Inhibitor of platelet activation by decreasing P-selectin expression | [ |
| Luteolin sulfate | 40 μM | Macrophages Raw 264.7 cells | Anti-inflammatory activities as inhibition of LPS-stimulated iNOS expression and production of nitric oxide, TNF-α, IL-1β, and IL-6 | [ |
| Luteolin glucuronide | 25–200 μg/mL | Macrophages Raw 264.7 cells | Anti-inflammatory activities as inhibition of LPS-stimulated iNOS expression and production of nitric oxide, TNF-α, IL-1β, and IL-6 | [ |
| 40 μM | Macrophages Raw 264.7 cells | Anti-inflammatory activities as inhibition of LPS-stimulated iNOS expression and production of nitric oxide, TNF-α, IL-1β, and IL-6 | [ | |
| 50 mM | Macrophages Raw 264.7 cells | Reduction of expression of LPS-stimulated inflammatory genes | [ | |
| Apigenin glucuronide | 25–100 μg/mL | Macrophages Raw 264.7 cells | Inhibition of Ox-LDL uptake and the scavenger receptor CD36 mRNA and protein expression. | [ |
| 12.5–100 µM | Macrophages Raw 264.7 cells | Counteraction of prostaglandin E2 (PGE2) production, LPS-induced mRNA expression of iNOS, COX-2 and TNF-α | [ |